Table 1 Baseline characteristics in RA patients who were receiving MTX and comparison between patients with and without abnormal liver stiffness measurement (LSM)
| Â | All patients (n= 105) | LSM < 5.3 kPa(n= 81) | LSM > 5.3 kPa(n= 24) | P-value |
|---|---|---|---|---|
Demographic variables | Â | Â | Â | Â |
Age, years | 54.0 (25, 73) | 52.5 ± 10.3 | 52.3 ± 11.8 | 0.852 |
Male gender | 20 (19.0) | 16 (19.8) | 4 (16.7) | 0.736 |
Body mass index, kg/m2 | 22.1 (18.1, 27.6) | 22.1 ± 2.5 | 22.3 ± 2.4 | 0.723 |
Metabolic syndrome, number patients (%) | 6 (5.7) | 3 (3.7) | 3 (12.5) | 0.105 |
Disease duration, weeks | 140.4 (26.1, 739.2) | 171.8 ± 123.9 | 240.5 ± 159 | 0.059 |
Laboratory variables | Â | Â | Â | Â |
C-reactive protein, mg/L | 1.2 (0, 124.0) | 3.1 ± 5.7 | 6.9 ± 25.1 | 0.766 |
Erythrocyte sedimentation rate, mm/hr | 33.0 (2, 111) | 37.3 ± 22.3 | 32.4 ± 20.7 | 0.362 |
White blood cells, count/mm3 | 5,960.0 (2,390.0, 12,870.0) | 6,355.9 ± 2,009.0 | 5,801.7 ± 1,853.9 | 0.319 |
Hemoglobin, g/dL | 12.7 (9.9, 16.2) | 12.7 ± 1.1 | 13.0 ± 1.0 | 0.324 |
Platelet count, × 1,000/mm3 | 241.0 (134.0, 470.0) | 253.0 ± 60.3 | 250.8 ± 69.0 | 0.723 |
Prothrombin time, INR | 0.9 (0.8, 1.2) | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.726 |
Glucose, mg/dL | 85.0 (70.0, 125.0) | 87.4 ± 10.7 | 86.4 ± 5.0 | 0.652 |
Blood urea nitrogen, mg/dL | 14.4 (0.9, 28.1) | 15.2 ± 4.8 | 14.1 ± 4.6 | 0.249 |
Creatinine mg/dL | 0.7 (0.5, 1.3) | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.858 |
Uric acid, mg/dL | 3.8 (1.5, 8.9) | 4.0 ± 1.2 | 4.1 ± 1.8 | 0.582 |
Aspartate aminotransferase, IU/L | 21.0 (13.0, 34.0) | 21.9 ± 5.5 | 22.4 ± 6.8 | 0.881 |
Alanine aminotransferase, IU/L | 17.0 (8.0, 39.0) | 18.9 ± 7.7 | 19.0 ± 7.7 | 0.879 |
Total protein, mg/dL | 6.9 (5.5, 7.9) | 7.0 ± 0.4 | 7.0 ± 0.5 | 0.730 |
Serum albumin, mg/dL | 4.3 (3.5, 4.9) | 4.3 ± 0.3 | 4.2 ± 0.4 | 0.815 |
Total bilirubin, mg/dL | 0.6 (0.2, 1.1) | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.461 |
Alkaline phosphatase, IU/L | 52.0 (38.0, 110.0) | 56.4 ± 17.0 | 54.7 ± 13.1 | 0.976 |
Gamma-glutamyltranspeptidase, IU/L | 17.0 (5.0, 53.0) | 22.6 ± 15.1 | 26.3 ± 19.1 | 0.340 |
Triglyceride, mg/dL | 90.0 (26.0, 269.0) | 108.9 ± 55.4 | 92.2 ± 41.4 | 0.197 |
High density cholesterol, mg/dL | 55.0 (19.0, 86.0) | 55.9 ± 10.4 | 53.2 ± 19.1 | 0.772 |
Low density cholesterol, mg/dL | 105.4 (52.8, 172.6) | 108.8 ± 26.8 | 107.4 ± 26.8 | 0.743 |
Cumulative dose of medication, mg | Â | Â | Â | Â |
Methotrexate (105 patients) | 2,032.5 (285.0, 7,800.0) | 2,334.0 ± 1,939.9 | 3,127.9 ± 2,072.7 | 0.086 |
Leflunomide (53 patients) | 7,800.0 (280.0, 38,520.0) | 9,291.1 ± 9,331.8 | 19,919.3 ± 12,716.8 | 0.008 |
Sulfasalazine (82 patients) | 360,000.0 (30,000.0, 6,028,000.0) | 727,778.7 ± 969,150.7 | 1,093,547.6 ± 1,330,930.2 | 0.111 |
Hydroxychloroquine (65 patients) | 94,600.0 (4,200.0, 868,000.0) | 115,248.0 ± 120,975.1 | 182,013.3 ± 208,807.9 | 0.129 |
Prednisolone (89 patients) | 3,015.0 (372.5, 20,212.5) | 4,642.1.0 ± 4,196.7 | 6,756.7.1 ± 6,156.5 | 0.472 |
Meloxicam (90 patients) | 6,273.8 (210.0, 2,895,000.0) | 90,205.0 ± 363,930.2 | 161,274.6 ± 644,791.4 | 0.793 |
Celecoxib (70 patients) | 163,000.0 (1,000.0, 1,503,000.0) | 218,505.7 ± 253,487.6 | 316,705.9 ± 313,982.7 | 0.239 |
LSM | Â | Â | Â | Â |
LSM, kPa, median (range) | 4.4 (2.8, 17.8) | NA | NA | NA |
LSM, kPa, median (IQR) | 0.14 (0.02, 0.29) | NA | NA | NA |
Success rate, %, median (IQR) | 100.0 (63.0, 100.0) | NA | NA | NA |